CSF lymphocytic pleocytosis does not predict a less favourable long-term prognosis in MS.
CSF lymphocytic pleocytosis does not predict a less favourable long-term prognosis in MS.
复制标题
CSF淋巴细胞性多细胞增多症不会预测MS中的长期预后不太有利。
DOI：
10.1007/s00415-022-11521-0
复制
发表时间：
2023-04
影响因子：
6
通讯作者：
Constantinescu, Cris S.
中科院分区：
文献类型：
--
作者：
Astbury, Lauren;Kalra, Seema;Tanasescu, Radu;Constantinescu, Cris S.
脑脊液淋巴细胞增多症在预测多发性硬化症临床预后中的作用尚不清楚。我们在英国的一个大型队列中探讨了脑脊液多细胞症在诊断时对长期疾病进展的影响。我们提取了1996年至2014年间在英国中部两个多发性硬化症中心就诊的多发性硬化症患者的人口学、临床和脑脊液数据。我们比较了发病时的EDSS，随访EDSS和进展指数多发性硬化症严重程度评分（MSSS）， EDSS的年化变化以及在存在/不存在多细胞增多症时向继发性进展的过渡。采用双尾学生t检验、Mann-Whitney U检验、卡方检验或Fisher精确检验来检测差异。共有247例MS患者（女性178例，平均年龄42.4岁，217例复发）被随访，平均13.56年（中位12年）。几乎18%的患者淋巴细胞CSF≥5 /微升。脑脊液多胞症与LP或随访时较高的EDSS以及其他进展指标（如mss、EDSS的年化变化或向继发性进展的过渡）无关。多发性硬化症诊断时脑脊液多细胞增多不能预测更高的长期残疾，在常规临床情况下也没有长期预后价值。MS人群之间的差异和CSF分析时疾病活动性的潜在差异可能解释了研究之间的差异。在线版本包含补充资料，下载地址：10.1007/s00415-022-11521-0。
The role of CSF lymphocytic pleocytosis in predicting the clinical outcome of multiple sclerosis is unclear. We explored the impact of CSF pleocytosis at diagnosis on long-term disease progression in a large UK cohort. We extracted demographic, clinical and CSF data of people with MS attending the MS clinics between 1996 and 2014 at two MS centres from the English Midlands. We compared EDSS at onset, follow up EDSS and progression indices Multiple Sclerosis Severity Score (MSSS), annualized change in EDSS and transition to secondary progression in the presence/absence of pleocytosis. Two-tailed student t-test, Mann–Whitney U test, Chi-Square or Fisher’s exact tests were used for detecting the differences. A total of 247 patients with MS (178 females; mean age 42.4; 217 with relapsing onset) were followed up for an average of 13.56 years (median 12 years). Almost 18% had lymphocytic CSF ≥ 5 per microliter. CSF pleocytosis was not associated with higher EDSS at the time of LP or at follow up, and other progression indices like MSSS, annualized change in EDSS or transition to secondary progression. CSF pleocytosis at MS diagnosis does not predict higher long-term disability and has no long-term prognostic value in routine clinical circumstances. Differences between MS populations and potential differences in disease activity at the time of CSF analysis may account for differences between studies. The online version contains supplementary material available at 10.1007/s00415-022-11521-0.
登录
查看更多内容
影响因子：
5.6
作者：
Schwenkenbecher P;Sarikidi A;Bönig L;Wurster U;Bronzlik P;Sühs KW;Pul R;Stangel M;Skripuletz T
通讯作者：
Skripuletz T
影响因子：
9.9
作者：
Roxburgh, RHSR;Seaman, SR;Compston, DAS
通讯作者：
Compston, DAS
影响因子：
14.5
作者：
Cepok, S;Jacobsen, M;Hemmer, B
通讯作者：
Hemmer, B
影响因子：
5.8
作者：
Eisele, Philipp;Szabo, Kristina;Gass, Achim
通讯作者：
Gass, Achim
影响因子：
--
作者：
Kwon, OJ;Karni, A;Karussis, D
通讯作者：
Karussis, D